SWOG S1803 (Multiple Myeloma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiply myeloma patients live longer.

What is the Condition Being Studied?

Multiple myeloma patients who have received a stem cell transplant

Who Can Participate in the Study?

Adults with multiple myeloma who have had a stem cell transplant.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be randomly assigned (like flipping a coin) to 1 of 2 groups
-- One group will take the standard maintenance drug, lenalidomide, and the study drug daratumumab/rHuPH20
-- The other group will take lenalidomide alone

Study Details

Full Title
SWOG S1803: Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator
Cellular Therapy Specialist
Protocol Number
IRB: PRO00104040
NCT: NCT04071457
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698